FOR PREVIEW ONLY (Print)

Paul Lapchak, FAHA, PhD

Director, Translational Research

Professor, Neurosurgery

Professor, Neurology

Send an Email

Research Office:

Phone:

310-248-8188

Paul Lapchak, FAHA, PhD

Director, Translational Research

Professor, Neurosurgery

Professor, Neurology

Paul Lapchak, PhD, FAHA, focuses on translational neurodegenerative disease research. The translational stroke research laboratory is developing new therapeutic approaches to treat acute ischemic stroke, hemorrhagic stroke, spinal cord ischemia and traumatic brain injury (TBI). As a primary focus, the lab is developing natural product analogs derived from plants and other natural sources and novel nanoparticles to treat stroke and TBI. The laboratory also applies new technologies to treat stroke and to follow the progression of stroke in vitro and in vivo. Current investigations include collaborative efforts with the pharmaceutical and biotechnology industries to assess the potential of novel molecules using the rabbit small clot embolic stroke model with the goal of filing INDs or NDAs. As a fee-for-service translational stroke laboratory, the lab can assist with academic or industrial ventures with de-risking the development of new therapeutics using the cost-effective rabbit small clot embolic stroke model. Important laboratory projects include researching and developing novel neuroprotective agents to attenuate ischemia-induced spinal cord injury and paraplegia, studying the role of cytochrome oxidase and trophic factors in laser-induced neuroprotection following stroke, developing therapies to use in combination with thrombolytics to treat stroke, and testing novel devices, including transcranial laser therapy and ultrasound, to treat stroke.

View NIH Biographical Sketch as a PDF

  • Undergraduate: Concordia University, 1984
  • Doctorate: McGill University, 1988
  • Post Doctorate: McGill Univsrsity, 1989
  • Post Doctorate: University Southern California, 1992

View CV as a PDF

  • Editor-in-Chief: Journal of Neurology & Neurophysiology, Current
  • Editorial Board Member: Journal of Neurology & Neurophysiology, Current
  • Editorial Board Member: Translational Stroke Research, 2010-12
  • Chartered Member, National Institute of Neurological Disorders and Stroke Study Section NSD-A, 2010
  • Fellow American Heart Association, 2010
  • American Heart Association, 2000
  • American Heart Association Stroke Council, 2000
  • Society for Neuroscience, 1984

Show moreShow less

Click here for a list of peer-reviewed publications.

  • Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841-843.
  • Lapchak PA. A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy. Transl Stroke Res. 2015;6(2):99-103.
  • Lapchak PA, Schubert DR, Maher P. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011;116(1):122-131.
  • Lapchak PA. Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res. 2013;4(6):704-709.
  • Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96-107.
  • Lapchak PA, Daley JT, Boitano PD. A blinded, randomized study of l-arginine in small clot embolized rabbits. Exp Neurol. 2015;266:143-146.

Show moreShow less

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Paul Lapchak, FAHA, PhD